Company / Revenue per Share
UroGen Pharma Ltd. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$2.60
FY2025
5-year range
$1.18 / $2.78
FY2021-FY2025
Trend
+120.4%
vs FY2024
Sector context
#80 of 154
Health Care
What the data says
At $2.60, UroGen Pharma Ltd.'s revenue per share ranks #80 of 154 in the Health Care sector. Revenue per Share has fluctuated over the past 10 years, ranging from $0.00 in FY2020 to $7.60 in FY2016.
Based on SEC 10-K filings.
2.60 in FY2025 with a 5-year CAGR of +397.1%.
Declined from $2.78 to $2.60 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +6.7%
- 5-Year CAGR
- +397.1%
- 10-Year CAGR
- -
Sector benchmark
#80 of 154 in Health CareTop 52% of 154This company $2.60 Sector average $15.09
▼
-82.8% below sector average
Key checks
Key Insights
- In FY2025, revenue per share increased 120.4% year-over-year.
- Ranks #80 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2016.
- Lowest revenue per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.60 | +120.4% |
| FY2024 | $1.18 | -57.6% |
| FY2023 | $2.78 | +30.1% |
| FY2022 | $2.14 | -1.3% |
| FY2021 | $2.17 | +253055.1% |
| FY2020 | $0.00 | -99.8% |
| FY2019 | $0.50 | +513.3% |
| FY2018 | $0.08 | -90.2% |
| FY2017 | $0.84 | -89.0% |
| FY2016 | $7.60 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026